Advanced search
Publication Cover
Pharmacogenomics Volume 12, 2011 - Issue 2
Submit an article Journal homepage
2,412
Views
0
CrossRef citations to date
0
Altmetric
Review

Absorption, Distribution, Metabolism and Excretion Pharmacogenomics of Drugs of Abuse

Markus R Meyer1 Department of Experimental & Clinical Toxicology, Institute of Experimental & Clinical Pharmacology & Toxicology, Saarland University, D 66421Homburg (Saar), Germany
&
Hans H Maurer1 Department of Experimental & Clinical Toxicology, Institute of Experimental & Clinical Pharmacology & Toxicology, Saarland University, D 66421Homburg (Saar), Germany;2 Tel.: +49 684 1162 6050 Fax: +49 684 1162 [email protected]
Pages 215-233 | Published online: 18 Feb 2011

Bibliography

  • Daly AK : Pharmacogenetics and human genetic polymorphisms.Biochem. J.429 , 435–449 (2010).
  • Hesselink DA , BouamarR, van Gelder T: The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther. Drug Monit.32(4) , 387–393 (2010).
  • Sheehan JJ , SliwaJK, AmatniekJC, GrinspanA, CanusoCM: Atypical antipsychotic metabolism and excretion.Curr. Drug Metab.11 , 516–525 (2010).
  • Ciarimboli G : Organic cation transporters.Xenobiotica38 , 936–971 (2008).
  • Eichelbaum M , Ingelman-SundbergM, EvansWE: Pharmacogenomics and individualized drug therapy.Annu. Rev. Med.57 , 119–137 (2006).
  • Shah RR : Can pharmacogenetics help rescue drugs withdrawn from the market?Pharmacogenomics7 , 889–908 (2006).
  • Zhang ZY , WongYN: Enzyme kinetics for clinically relevant CYP inhibition.Curr. Drug Metab.6 , 241–257 (2005).
  • Tang C , LinJH, LuAY: Metabolism-based drug–drug interactions: what determines individual variability in cytochrome P450 induction?Drug Metab. Dispos.33 , 603–613 (2005).
  • Lotsch J , SkarkeC, LiefholdJ, GeisslingerG: Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.Clin. Pharmacokinet.43 , 983–1013 (2004).
  • Zanger UM , RaimundoS, EichelbaumM: Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.Naunyn Schmiedebergs Arch. Pharmacol.369 , 23–37 (2004).
  • Evans WE , McLeodHL: Pharmacogenomics-drug disposition, drug targets, and side effects.N. Engl. J. Med.348 , 538–549 (2003).
  • Pritzker D , KanungoA, KilicarslanT, TyndaleRF, SellersEM: Designer drugs that are potent inhibitors of CYP2D6.J. Clin. Psychopharmacol.22 , 330–332 (2002).
  • Antoniou T , TsengAL: Interactions between recreational drugs and antiretroviral agents.Ann. Pharmacother.36 , 1598–1613 (2002).
  • Rendic S : Summary of information on human CYP enzymes: human P450 metabolism data.Drug Metab. Rev.34 , 83–448 (2002).
  • Howard LA , SellersEM, TyndaleRF: The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence.Pharmacogenomics3 , 185–199 (2002).
  • Ingelman-Sundberg M : Polymorphism of cytochrome P450 and xenobiotic toxicity.Toxicology181–182, 447–452 (2002).
  • Zhou SF , LiuJP, ChowbayB: Polymorphism of human cytochrome P450 enzymes and its clinical impact.Drug Metab. Rev.41 , 89–295 (2009).
  • Zhou SF : Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.Clin. Pharmacokinet.48 , 761–804 (2009).
  • Suzuki Y , SugaiT, FukuiN et al.: CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype–phenotype association study design in translational pharmacogenetics.J. Psychopharmacol. (2010) (Epub ahead of print).
  • Chan WH , ChenTL, ChenRM, SunWZ, UengTH: Propofol metabolism is enhanced after repetitive ketamine administration in rats: the role of cytochrome P-450 2B induction.Br. J. Anaesth.97 , 351–358 (2006).
  • Wojnowski L : Genetics of the variable expression of CYP3A in humans.Ther. Drug Monit.26 , 192–199 (2004).
  • Gibson GG , PlantNJ, SwalesKE, AyrtonA, El Sankary W: Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica32 , 165–206 (2002).
  • Evans AM : Influence of dietary components on the gastrointestinal metabolism and transport of drugs.Ther. Drug Monit.22 , 131–136 (2000).
  • Ozdemir V , KalowaW, TangBK et al.: Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.Pharmacogenetics10 , 373–388 (2000).
  • Crettol S , PetrovicN, MurrayM: Pharmacogenetics of phase I and phase II drug metabolism.Curr. Pharm. Des.16 , 204–219 (2010).
  • Hayes JD , StrangeRC: Glutathione S-transferase polymorphisms and their biological consequences.Pharmacology61 , 154–166 (2000).
  • Staatz CE , GoodmanLK, TettSE: Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II.Clin. Pharmacokinet.49 , 207–221 (2010).
  • Maurer HH , SauerC, TheobaldDS: Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine.Ther. Drug Monit.28 , 447–453 (2006).
  • Kraemer T , MaurerHH: Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, of amphetamine, methamphetamine and their N-alkyl derivatives.Ther. Drug Monit.24 , 277–289 (2002).
  • Staack RF , MaurerHH: Metabolism of designer drugs of abuse.Curr. Drug Metab.6 , 259–274 (2005).
  • Meyer MR , MaurerHH: Metabolism of designer drugs of abuse: an updated review.Curr. Drug Metab.11 , 468–482 (2010).
  • Vandevenne M , VandenbusscheH, VerstraeteA: Detection time of drugs of abuse in urine.Acta Clin. Belg.55 , 323–333 (2000).
  • Verstraete AG : Detection times of drugs of abuse in blood, urine, and oral fluid.Ther. Drug Monit.26 , 200–205 (2004).
  • Maurer HH : Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control.Clin. Chem. Lab. Med.42 , 1310–1324 (2004).
  • Maurer HH : The relevance of pharmacogenetics and of metabolic interactions for clinical and forensic toxicology. In: Proceedings of the XIIIth GTFCh Symposium in Mosbach. Pragst F, Aderjan R (Eds). Helm-Verlag, Heppenheim, Germany, 197–203 (2003).
  • Maurer HH : Toxicokinetics – variations due to genetics or interactions: basics and examples. In: Current Contributions to Forensic and Clinical Toxicology. Pragst F, Aderjan R (Eds). GTFCH, Bad Vilbel, Germany, 153–155 (2008).
  • Smith HS : Opioid metabolism.Mayo Clin. Proc.84 , 613–624 (2009).
  • Stamer UM , ZhangL, StuberF: Personalized therapy in pain management: where do we stand?Pharmacogenomics11 , 843–864 (2010).
  • Gilson AM , KreisPG: The burden of the nonmedical use of prescription opioid analgesics.Pain Med.10(Suppl. 2) , S89–S100 (2009).
  • Yamamoto Y , SmithRR, BernankeDH: Accelerated nonmuscle contraction after subarachnoid hemorrhage: culture and characterization of myofibroblasts from human cerebral arteries in vasospasm.Neurosurgery30 , 337–345 (1992).
  • Kalso E : Oxycodone.J. Pain Symptom. Manage.29 , S47–S56 (2005).
  • Lalovic B , PhillipsB, RislerLL, HowaldW, ShenDD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.Drug Metab. Dispos.32 , 447–454 (2004).
  • Nieminen TH , HagelbergNM, SaariTI et al.: Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.Anesthesiology110 , 1371–1378 (2009).
  • Samer CF , DaaliY, WagnerM et al.: Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.Br. J. Pharmacol.160 , 919–930 (2010).
  • Lee HK , LewisLD, TsongalisGJ et al.: Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism.Clin. Chim. Acta367 , 196–200 (2006).
  • Sasaki T , EkinoS, YonemasuK: Effect of bursectomy on serum levels of chicken complement component C1q.Dev. Comp. Immunol.16 , 257–261 (1992).
  • Otton SV , SchadelM, CheungSW et al.: CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.Clin. Pharmacol. Ther.54 , 463–472 (1993).
  • Sullivan HR , DueSL: Urinary metabolites of dl-methadone in maintenance subjects.J. Med. Chem.16 , 909–913 (1973).
  • Eap CB , BuclinT, BaumannP: Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.Clin. Pharmacokinet.41 , 1153–1193 (2002).
  • Crettol S , DeglonJJ, BessonJ et al.: ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.Clin. Pharmacol. Ther.80 , 668–681 (2006).
  • Wang H , TompkinsLM: CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.Curr. Drug Metab.9 , 598–610 (2008).
  • Zanger UM , KleinK, SausseleT et al.: Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.Pharmacogenomics8 , 743–759 (2007).
  • Totah RA , SheffelsP, RobertsT et al.: Role of CYP2B6 in stereoselective human methadone metabolism.Anesthesiology108 , 363–374 (2008).
  • Li Y , KantelipJP, Gerritsen-van Schieveen P, Davani S: Interindividual variability of methadone response: impact of genetic polymorphism. Mol. Diagn. Ther.12 , 109–124 (2008).
  • Finch JS , DeKornfeldTJ: Clinical investigation of the analgesic potency and respiratory depressant activity of fentanyl, a new narcotic analgesic.J. Clin. Pharmacol. J. New Drugs7 , 46–51 (1967).
  • Labroo RB , PaineMF, ThummelKE, KharaschED: Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions.Drug Metab. Dispos.25 , 1072–1080 (1997).
  • Silverstein JH , RiedersMF, McMullinM, SchulmanS, ZahlK: An analysis of the duration of fentanyl and its metabolites in urine and saliva.Anesth. Analg.76 , 618–621 (1993).
  • Tateishi T , KrivorukY, UengYF et al.: Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation.Anesth. Analg.82 , 167–172 (1996).
  • Feierman DE , LaskerJM: Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.Drug Metab. Dispos.24 , 932–939 (1996).
  • Park HJ , ShinnHK, RyuSH et al.: Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans.Clin. Pharmacol. Ther.81 , 539–546 (2007).
  • Henthorn TK , LiuY, MahapatroM, NgKY: Active transport of fentanyl by the blood–brain barrier.J. Pharmacol. Exp. Ther.289 , 1084–1089 (1999).
  • Elkiweri IA , ZhangYL, ChristiansU et al.: Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats.Anesth. Analg.108 , 149–159 (2009).
  • Huang P , KehnerGB, CowanA, Liu-ChenLY: Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.J. Pharmacol. Exp. Ther.297 , 688–695 (2001).
  • Iribarne C , PicartD, DreanoY, BailJP, BerthouF: Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes.Life Sci.60 , 1953–1964 (1997).
  • Kobayashi K , YamamotoT, ChibaK et al.: Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4.Drug Metab. Dispos.26 , 818–821 (1998).
  • Picard N , CresteilT, DjebliN, MarquetP: In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.Drug Metab. Dispos.33 , 689–695 (2005).
  • Bruce RD , McCance-KatzE, KharaschED, MoodyDE, MorseGD: Pharmacokinetic interactions between buprenorphine and antiretroviral medications.Clin. Infect. Dis.43(Suppl. 4) , S216–S223 (2006).
  • McCance-Katz EF , MoodyDE, MorseGD et al.: Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.Drug Alcohol Depend.91 , 269–278 (2007).
  • Cone EJ , GorodetzkyCW, YousefnejadD, BuchwaldWF, JohnsonRE: The metabolism and excretion of buprenorphine in humans.Drug Metab. Dispos.12 , 577–581 (1984).
  • King CD , GreenMD, RiosGR et al.: The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1.Arch. Biochem. Biophys.332 , 92–100 (1996).
  • Chang Y , MoodyDE: Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases.Drug Metab. Lett.3 , 101–107 (2009).
  • Green MD , KingCD, MojarrabiB, MackenziePI, TephlyTR: Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3.Drug Metab. Dispos.26 , 507–512 (1998).
  • Rios GR , TephlyTR: Inhibition and active sites of UDP-glucuronosyltransferases 2B7 and 1A1.Drug Metab. Dispos.30 , 1364–1367 (2002).
  • Rouguieg K , PicardN, SauvageFL, GaulierJM, MarquetP: Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes.Drug Metab. Dispos.38 , 40–45 (2010).
  • Driessen B , ReimannW, GiertzH: Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro.Br. J. Pharmacol.108 , 806–811 (1993).
  • Driessen B , ReimannW: Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro.Br. J. Pharmacol.105 , 147–151 (1992).
  • Gillen C , HaurandM, KobeltDJ, WnendtS: Affinity, potency and efficacy of tramadol and its metabolites at the cloned human µ-opioid receptor.Naunyn Schmiedebergs Arch. Pharmacol.362 , 116–121 (2000).
  • Subrahmanyam V , RenwickAB, WaltersDG et al.: Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes.Drug Metab. Dispos.29 , 1146–1155 (2001).
  • Pedersen RS , DamkierP, BrosenK: Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.Eur. J. Clin. Pharmacol.62 , 513–521 (2006).
  • Stamer UM , MusshoffF, KobilayM et al.: Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.Clin. Pharmacol. Ther.82 , 41–47 (2007).
  • Kreek MJ , BartG, LillyC, LaForgeKS, NielsenDA: Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments.Pharmacol. Rev.57 , 1–26 (2005).
  • Kamendulis LM , BrzezinskiMR, PindelEV, BosronWF, DeanRA: Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases.J. Pharmacol. Exp. Ther.279 , 713–717 (1996).
  • Bencharit S , MortonCL, XueY, PotterPM, RedinboMR: Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme.Nat. Struct. Biol.10 , 349–356 (2003).
  • Brzezinski MR , SpinkBJ, DeanRA et al.: Human liver carboxylesterase hCE-1: binding specificity for cocaine, heroin, and their metabolites and analogs.Drug Metab. Dispos.25 , 1089–1096 (1997).
  • Kilpatrick GJ , SmithTW: Morphine-6-glucuronide: actions and mechanisms.Med. Res. Rev.25 , 521–544 (2005).
  • Stone AN , MackenziePI, GaletinA, HoustonJB, MinersJO: Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.Drug Metab. Dispos.31 , 1086–1089 (2003).
  • Projean D , MorinPE, TuTM, DucharmeJ: Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes.Xenobiotica33 , 841–854 (2003).
  • Skarke C , SchmidtH, GeisslingerG, DarimontJ, LotschJ: Pharmacokinetics of morphine are not altered in subjects with Gilbert‘s syndrome.Br. J. Clin. Pharmacol.56 , 228–231 (2003).
  • Fujita KI , AndoY, YamamotoW et al.: Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer.Cancer Chemother. Pharmacol. (2009) (Epub ahead of print).
  • Sindrup SH , BrosenK, BjerringP et al.: Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine.Clin. Pharmacol. Ther.48 , 686–693 (1990).
  • Yue QY , AlmC, SvenssonJO, SaweJ: Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators.Ther. Drug Monit.19 , 539–542 (1997).
  • Kathiramalainathan K , KaplanHL, RomachMK et al.: Inhibition of cytochrome P450 2D6 modifies codeine abuse liability.J. Clin. Psychopharmacol.20 , 435–444 (2000).
  • Yue QY , SaweJ: Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes.Eur. J. Clin. Pharmacol.52 , 41–47 (1997).
  • Caraco Y , TateishiT, GuengerichFP, WoodAJ: Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity.Drug Metab. Dispos.24 , 761–764 (1996).
  • Court MH , KrishnaswamyS, HaoQ et al.: Evaluation of 3´-azido-3´-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism.Drug Metab. Dispos.31 , 1125–1133 (2003).
  • Madadi P , RossCJ, HaydenMR et al.: Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case–control study.Clin. Pharmacol. Ther.85 , 31–35 (2009).
  • Gasche Y , DaaliY, FathiM et al.: Codeine intoxication associated with ultrarapid CYP2D6 metabolism.N. Engl. J. Med.351 , 2827–2831 (2004).
  • Nicholson KL , BalsterRL: GHB: a new and novel drug of abuse.Drug Alcohol Depend.63 , 1–22 (2001).
  • Kugelberg FC , HolmgrenA, EklundA, JonesAW: Forensic toxicology findings in deaths involving γ-hydroxybutyrate.Int. J. Legal Med.124 , 1–6 (2010).
  • Kuiper MA , PeikertN, BoermaEC: γ-hydroxybutyrate withdrawal syndrome: a case report.Cases J.2 , 6530 (2009).
  • Tarabar AF , NelsonLS: The γ-hydroxybutyrate withdrawal syndrome.Toxicol. Rev.23 , 45–49 (2004).
  • van Noorden MS , van Dongen LC, Zitman FG, Vergouwen TA: γ-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. Gen. Hosp. Psychiatry31 , 394–396 (2009).
  • Lyon RC , JohnstonSM, PanopoulosA et al.: Enzymes involved in the metabolism of γ-hydroxybutyrate in SH-SY5Y cells: identification of an iron-dependent alcohol dehydrogenase ADHFe1.Chem. Biol. Interact.178 , 283–287 (2009).
  • Bessman SP , FishbeinWN: γ-hydroxybutyrate, a normal brain metabolite.Nature200 , 1207–1208 (1963).
  • Drasbek KR , ChristensenJ, JensenK: γ-hydroxybutyrate – a drug of abuse.Acta Neurol. Scand.114 , 145–156 (2006).
  • Vayer P , MandelP, MaitreM: Conversion of γ-hydroxybutyrate to γ-aminobutyrate in vitro.J. Neurochem.45 , 810–814 (1985).
  • Park J , OseiYD, ChurchichJE: Isolation and characterization of recombinant mitochondrial 4-aminobutyrate aminotransferase.J. Biol. Chem.268 , 7636–7639 (1993).
  • O‘Connor T , IrelandLS, HarrisonDJ, HayesJD: Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.Biochem. J.343(Pt 2) , 487–504 (1999).
  • York JL , GrollmanAP, BublitzC: TPN-L-gluonate dehydrogenase.Biochim. Biophys. Acta47 , 298–306 (1961).
  • Vayer P , SchmittM, BourguignonJJ, MandelP, MaitreM: Evidence for a role of high Km aldehyde reductase in the degradation of endogenous γ-hydroxybutyrate from rat brain.FEBS Lett.190 , 55–60 (1985).
  • Kaufman EE , NelsonT, FalesHM, LevinDM: Isolation and characterization of a hydroxyacid-oxoacid transhydrogenase from rat kidney mitochondria.J. Biol. Chem.263 , 16872–16879 (1988).
  • Struys EA , VerhoevenNM, Ten Brink HJ et al.: Kinetic characterization of human hydroxyacid-oxoacid transhydrogenase: relevance to D-2-hydroxyglutaric and γ-hydroxybutyric acidurias. J. Inherit. Metab. Dis.28 , 921–930 (2005).
  • Kaufman EE , NelsonT: An overview of γ-hydroxybutyrate catabolism: the role of the cytosolic NADP(+)-dependent oxidoreductase EC 1.1.1.19 and of a mitochondrial hydroxyacid-oxoacid transhydrogenase in the initial, rate-limiting step in this pathway.Neurochem. Res.16 , 965–974 (1991).
  • Gibson KM , HoffmannGF, HodsonAK, BottiglieriT, JakobsC: 4-Hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn error of GABA metabolism.Neuropediatrics29 , 14–22 (1998).
  • Andresen H , SprysN, SchmoldtA, MuellerA, Iwersen-BergmannS: γ-hydroxybutyrate in urine and serum: additional data supporting current cut-off recommendations.Forensic Sci. Int.200 , 93–99 (2010).
  • Wilson C , CanningP, CaravatiEM: The abuse potential of propofol.Clin. Toxicol. (Phila.)48 , 165–170 (2010).
  • Hetz G : [How expensive must a treatment room be?].Zahnarztl. Prax.42 , 91–92 (1991).
  • Simons PJ , CockshottID, DouglasEJ et al.: Species differences in blood profiles, metabolism and excretion of 14C-propofol after intravenous dosing to rat, dog and rabbit.Xenobiotica21 , 1243–1256 (1991).
  • Sneyd JR , SimonsPJ, WrightB: Use of proton NMR spectroscopy to measure propofol metabolites in the urine of the female Caucasian patient.Xenobiotica24 , 1021–1028 (1994).
  • Yamazaki H , ShimizuM, NagashimaT, MinoshimaM, MurayamaN: Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol.Drug Metab. Dispos.34 , 1803–1805 (2006).
  • Donato MT , MonteroS, CastellJV, Gomez-LechonMJ, LahozA: Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies.Anal. Bioanal. Chem.396 , 2251–2263 (2010).
  • Fujiwara R , NakajimaM, YamanakaH et al.: Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms.Drug Metab. Dispos.35 , 747–757 (2007).
  • Court MH , DuanSX, HesseLM, VenkatakrishnanK, GreenblattDJ: Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes.Anesthesiology94 , 110–119 (2001).
  • Murayama N , MinoshimaM, ShimizuM, GuengerichFP, YamazakiH: Involvement of human cytochrome P450 2B6 in the ω- and 4-hydroxylation of the anesthetic agent propofol.Xenobiotica37 , 717–724 (2007).
  • Oda Y , HamaokaN, HiroiT et al.: Involvement of human liver cytochrome P4502B6 in the metabolism of propofol.Br. J. Clin. Pharmacol.51 , 281–285 (2001).
  • Favetta P , DegouteCS, PerdrixJP et al.: Propofol metabolites in man following propofol induction and maintenance.Br. J. Anaesth.88 , 653–658 (2002).
  • Takahashi H , MaruoY, MoriA et al.: Effect of D256N and Y483D on propofol glucuronidation by human uridine 5´-diphosphate glucuronosyltransferase (UGT1A9).Basic Clin. Pharmacol. Toxicol.103 , 131–136 (2008).
  • Rang HP , DaleMM, RitterJM: Pharmacology, 6th Edition. Churchill Livingston, London, UK, 532–533 (2007).
  • Hirota K , LambertDG: Ketamine: its mechanism(s) of action and unusual clinical uses.Br. J. Anaesth.77 , 441–444 (1996).
  • Anis NA , BerrySC, BurtonNR, LodgeD: The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate.Br. J. Pharmacol.79 , 565–575 (1983).
  • Gill PA : Non-medical use of ketamine.BMJ306 , 1340 (1993).
  • Pal HR , BerryN, KumarR, RayR: Ketamine dependence.Anaesth. Intensive Care30 , 382–384 (2002).
  • Curran HV , MorganC: Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later.Addiction95 , 575–590 (2000).
  • Curran HV , MonaghanL: In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users.Addiction96 , 749–760 (2001).
  • Wang YC , ChenSK, LinCM: Breaking the drug addiction cycle is not easy in ketamine abusers.Int. J. Urol.17 , 496 (2010).
  • Adams JD Jr, Baillie TA, Trevor AJ, Castagnoli N Jr: Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations. Biomed. Mass Spectrom.8 , 527–538 (1981).
  • Chang T , GlazkoAJ: Biotransformation and disposition of ketamine.Int. Anesthesiol. Clin.12 , 157–177 (1974).
  • Turfus SC , ParkinMC, CowanDA et al.: Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry.Drug Metab. Dispos.37 , 1769–1778 (2009).
  • Adamowicz P , KalaM: Urinary excretion rates of ketamine and norketamine following therapeutic ketamine administration: method and detection window considerations.J. Anal. Toxicol.29 , 376–382 (2005).
  • Cheng PS , FuCY, LeeCH, LiuC, ChienCS: GC-MS quantification of ketamine, norketamine, and dehydronorketamine in urine specimens and comparative study using ELISA as the preliminary test methodology.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.852 , 443–449 (2007).
  • Yanagihara Y , KariyaS, OhtaniM et al.: Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes.Drug Metab. Dispos.29 , 887–890 (2001).
  • Hijazi Y , BoulieuR: Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes.Drug Metab. Dispos.30 , 853–858 (2002).
  • Persson J , HasselstromJ, MaursetA et al.: Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity.Eur. J. Clin. Pharmacol.57 , 869–875 (2002).
  • Isaacs SO , MartinP, WashingtonJA Jr: Phencyclidine (PCP) abuse. A close-up look at a growing problem. Oral Surg. Oral Med. Oral Pathol.61 , 126–129 (1986).
  • Sauer C , PetersFT, StaackRF, FritschiG, MaurerHH: Metabolism and toxicological detection of a new designer drug, N-(1-phenylcyclohexyl)propanamine, in rat urine using gas chromatography-mass spectrometry.J. Chromatogr. A1186 , 380–390 (2008).
  • Sauer C , PetersFT, StaackRF, FritschiG, MaurerHH: Metabolism and toxicological detection of the designer drug N-(1-phenylcyclohexyl)-3-methoxypropanamine (PCMPA) in rat urine using gas chromatography-mass spectrometry.Forensic Sci. Int.181 , 47–51 (2008).
  • Sauer C , PetersFT, StaackRF, FritschiG, MaurerHH: New designer drug (1-(1-phenylcyclohexyl)-3-ethoxypropylamine (PCEPA): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry.J. Mass Spectrom.41 , 1014–1029 (2006).
  • Sauer C , PetersFT, StaackRF, FritschiG, MaurerHH: New designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques.J. Mass Spectrom.43 , 305–316 (2008).
  • Takeda H , GazzaraRA, HowardSG: Phenylcyclohexylamine: effect of a metabolite of phencyclidine on the efflux of dopamine in the rat.Neuropharmacology25 , 1341–1345 (1986).
  • Cook CE , BrineDR, QuinGD, Perez-ReyesM, Di Guiseppi SR: Phencyclidine and phenylcyclohexene disposition after smoking phencyclidine. Clin. Pharmacol. Ther.31 , 635–641 (1982).
  • Cook CE , BrineDR, JeffcoatAR et al.: Phencyclidine disposition after intravenous and oral doses.Clin. Pharmacol. Ther.31 , 625–634 (1982).
  • Laurenzana EM , OwensSM: Metabolism of phencyclidine by human liver microsomes.Drug Metab. Dispos.25 , 557–563 (1997).
  • Cook CE , JeffcoatAR, Perez-ReyesM: Pharmacokinetic studies of cocaine and phencyclidine in man. In: Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs. Barnett G, Chiang CN (Eds). Biomedical Publications, Forest City, CA, USA, 48–74 (1985).
  • Jushchyshyn MI , KentUM, HollenbergPF: The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine.Drug Metab. Dispos.31 , 46–52 (2003).
  • Sauer C , PetersFT, SchwaningerAE, MeyerMR, MaurerHH: Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-3-ethoxypropanamine (PCEPA) and N-(1-phenylcyclohexyl)-3-methoxypropanamine (PCMPA).Chem. Res. Toxicol.21 , 1949–1955 (2008).
  • Sauer C , PetersFT, SchwaningerAE, MeyerMR, MaurerHH: Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine.Biochem. Pharmacol.77 , 444–450 (2009).
  • Shimada T , YamazakiH, MimuraM, InuiY, GuengerichFP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.J. Pharmacol. Exp. Ther.270 , 414–423 (1994).
  • de Jongh R , BoltI, SchermerM, OlivierB: Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories.Neurosci. Biobehav. Rev.32 , 760–776 (2008).
  • Sahakian B , Morein-ZamirS: Professor‘s little helper.Nature450 , 1157–1159 (2007).
  • Solanto MV : Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration.Behav. Brain Res.94 , 127–152 (1998).
  • Volkow ND , WangG, FowlerJS et al.: Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.J. Neurosci.21(2) , RC121 (2001).
  • Swanson J , GuptaS, GuintaD et al.: Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.Clin. Pharmacol. Ther.66 , 295–305 (1999).
  • Bogle KE , SmithBH: Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences.Curr. Drug Abuse Rev.2 , 157–176 (2009).
  • Rabiner DL , AnastopoulosAD, CostelloEJ, HoyleRH, SwartzwelderHS: Predictors of nonmedical ADHD medication use by college students.J. Atten. Disord.13 , 640–648 (2010).
  • Tuttle JP , ScheurichNE, RanseenJ: Prevalence of ADHD diagnosis and nonmedical prescription stimulant use in medical students.Acad. Psychiatry34 , 220–223 (2010).
  • Faraj BA , IsrailiZH, PerelJM et al.: Metabolism and disposition of methylphenidate-14C: studies in man and animals.J. Pharmacol. Exp. Ther.191 , 535–547 (1974).
  • Patrick KS , KiltsCD, BreeseGR: Synthesis and pharmacology of hydroxylated metabolites of methylphenidate.J. Med. Chem.24 , 1237–1240 (1981).
  • Redalieu E , BartlettMF, WaldesLM et al.: A study of methylphenidate in man with respect to its major metabolite.Drug Metab. Dispos.10 , 708–709 (1982).
  • Aoyama T , KotakiH, HondaY, NakagawaF: Kinetic analysis of enantiomers of threo-methylphenidate and its metabolite in two healthy subjects after oral administration as determined by a gas chromatographic-mass spectrometric method.J. Pharm. Sci.79 , 465–469 (1990).
  • Sun Z , MurryDJ, SanghaniSP et al.: Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1.J. Pharmacol. Exp. Ther.310 , 469–476 (2004).
  • LeVasseur NL , ZhuHJ, MarkowitzJS, DeVaneCL, PatrickKS: Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.862 , 140–149 (2008).
  • Zhu HJ , AppelDI, PetersonYK, WangZ, MarkowitzJS: Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions.Toxicology270 , 59–65 (2010).
  • Koehm M , KauertGF, ToennesSW: Influence of ethanol on the pharmacokinetics of methylphenidate‘s metabolites ritalinic acid and ethylphenidate.Arzneimittelforschung60 , 238–244 (2010).
  • Patrick KS , StraughnAB, MinhinnettRR et al.: Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics.Clin. Pharmacol. Ther.81 , 346–353 (2007).
  • Zhu HJ , PatrickKS, YuanHJ et al.: Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis.Am. J. Hum. Genet.82 , 1241–1248 (2008).
  • Repantis D , SchlattmannP, LaisneyO, HeuserI: Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review.Pharmacol. Res.62 , 187–206 (2010).
  • Maher B : Poll results: look who‘s doping.Nature452 , 674–675 (2008).
  • Tao G , LongshanZ, KehuaW et al.: Population pharmacokinetics of modafinil in Chinese Han, Mongolian, Korean, Uygur, and Hui healthy subjects determined by nonlinear mixed-effects modeling.Ther. Drug Monit.32 , 189–193 (2010).
  • Wong YN , KingSP, SimcoeD et al.: Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects.J. Clin. Pharmacol.39 , 281–288 (1999).
  • Burnat P , RoblesF, DoB: High-performance liquid chromatographic determination of modafinil and its two metabolites in human plasma using solid-phase extraction.J. Chromatogr. B706 , 295–304 (1998).
  • Tseng YL , UraletsV, LinCT, KuoFH: Detection of modafinil in human urine by gas chromatography-mass spectrometry.J. Pharm. Biomed. Anal.39 , 1042–1045 (2005).
  • Donovan JL , MalcolmRJ, MarkowitzJS, DeVaneCL: Chiral analysis of D- and L-modafinil in human serum: application to human pharmacokinetic studies.Ther. Drug Monit.25 , 197–202 (2003).
  • Robertson P , DeCoryHH, MadanA, ParkinsonA: In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.Drug Metab. Dispos.28 , 664–671 (2000).
  • Darwish M , KirbyM, RobertsonP Jr, Hellriegel ET: Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin. Pharmacokinet.47 , 61–74 (2008).
  • Zhu HJ , WangJS, DonovanJL et al.: Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.Eur. J. Pharmacol.578 , 148–158 (2008).
  • Passie T , HalpernJH, StichtenothDO, EmrichHM, HintzenA: The pharmacology of lysergic acid diethylamide: a review.CNS Neurosci. Ther.14 , 295–314 (2008).
  • Poch GK , KletteKL, HallareDA et al.: Detection of metabolites of lysergic acid diethylamide (LSD) in human urine specimens: 2-oxo-3-hydroxy-LSD, a prevalent metabolite of LSD.J. Chromatogr. B Biomed. Sci. Appl.724 , 23–33 (1999).
  • Reuschel SA , EadesD, FoltzRL: Recent advances in chromatographic and mass spectrometric methods for determination of LSD and its metabolites in physiological specimens.J. Chromatogr. B Biomed. Sci. Appl.733 , 145–159 (1999).
  • Nelson CC , FoltzRL: Chromatographic and mass spectrometric methods for determination of lysergic acid diethylamide (LSD) and metabolites in body fluids.J. Chromatogr.580 , 97–109 (1992).
  • Klette KL , AndersonCJ, PochGK, NimrodAC, ElSohlyMA: Metabolism of lysergic acid diethylamide (LSD) to 2-oxo-3-hydroxy LSD (O-H-LSD) in human liver microsomes and cryopreserved human hepatocytes.J. Anal. Toxicol.24 , 550–556 (2000).
  • Verstraete AG , Van de Velde EJ: 2-oxo-3-hydroxy-LSD: an important LSD metabolite? Acta Clin. Belg. Suppl.1 , 94–96 (1999).
  • Yu AM : Indolealkylamines: biotransformations and potential drug–drug interactions.AAPS J.10 , 242–253 (2008).
  • Valdes LJ III: Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. J. Psychoactive Drugs26 , 277–283 (1994).
  • Roth BL , BanerK, WestkaemperR et al.: Salvinorin A: a potent naturally occurring nonnitrogenous κ opioid selective agonist.Proc. Natl Acad. Sci. USA99 , 11934–11939 (2002).
  • Gonzalez D , RibaJ, BousoJC, Gomez-JaraboG, BarbanojMJ: Pattern of use and subjective effects of Salvia divinorum among recreational users.Drug Alcohol Depend.85 , 157–162 (2006).
  • Schmidt MS , PrisinzanoTE, TidgewellK et al.: Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.818 , 221–225 (2005).
  • Valdes LJ III, Chang HM, Visger DC, Koreeda M: Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum. Org. Lett.3 , 3935–3937 (2001).
  • Schmidt MD , SchmidtMS, ButelmanER et al.: Pharmacokinetics of the plant-derived k-opioid hallucinogen salvinorin A in nonhuman primates.Synapse58 , 208–210 (2005).
  • Teksin ZS , LeeIJ, NemiebokaNN et al.: Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.Eur. J. Pharm. Biopharm.72(2) , 471–477 (2009).
  • Hasler F , BourquinD, BrenneisenR, BarT, VollenweiderFX: Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man.Pharm. Acta Helv.72 , 175–184 (1997).
  • Passie T , SeifertJ, SchneiderU, EmrichHM: The pharmacology of psilocybin.Addict. Biol.7 , 357–364 (2002).
  • Gonzalez-Maeso J , WeisstaubNV, ZhouM et al.: Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.Neuron53 , 439–452 (2007).
  • Grieshaber AF , MooreKA, LevineB: The detection of psilocin in human urine.J. Forensic Sci.46 , 627–630 (2001).
  • Sticht G , KafersteinH: Detection of psilocin in body fluids.Forensic Sci. Int.113 , 403–407 (2000).
  • Kamata T , NishikawaM, KatagiM, TsuchihashiH: Direct detection of serum psilocin glucuronide by LC/MS and LC/MS/MS: time-courses of total and free (unconjugated) psilocin concentrations in serum specimens of a ‘magic mushroom‘ user.Forensic Toxicol.24 , 36–40 (2006).
  • Manevski N , KurkelaM, HöglundC et al.: Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases.Drug Metab. Dispos.38(3) , 386–395 (2010).
  • Benowitz NL : Nicotine addiction.N. Engl. J. Med.362 , 2295–2303 (2010).
  • Hukkanen J , JacobP III, Benowitz NL: Metabolism and disposition kinetics of nicotine. Pharmacol. Rev.57 , 79–115 (2005).
  • Benowitz NL , HukkanenJ, JacobP III: Nicotine chemistry, metabolism, kinetics and biomarkers. Handb. Exp. Pharmacol.192 , 29–60 (2009).
  • Malaiyandi V , SellersEM, TyndaleRF: Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.Clin. Pharmacol. Ther.77 , 145–158 (2005).
  • Lerman C , TyndaleR, PattersonF et al.: Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation.Clin. Pharmacol. Ther.79 , 600–608 (2006).
  • Rubinstein ML , BenowitzNL, AuerbackGM, MoscickiAB: Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers.Pediatrics122 , e643–e647 (2008).
  • Dempsey D , TutkaP, JacobP III et al.: Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther.76 , 64–72 (2004).
  • Swan GE , BenowitzNL, LessovCN et al.: Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence.Pharmacogenet. Genomics15 , 115–125 (2005).
  • Nakajima M , KuroiwaY, YokoiT: Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6.Drug Metab. Rev.34 , 865–877 (2002).
  • Benowitz NL , Perez-StableEJ, FongI et al.: Ethnic differences in N-glucuronidation of nicotine and cotinine.J. Pharmacol. Exp. Ther.291 , 1196–1203 (1999).
  • Perez-Stable EJ , HerreraB, JacobP III, Benowitz NL: Nicotine metabolism and intake in black and white smokers. JAMA280 , 152–156 (1998).
  • Benowitz NL , Perez-StableEJ, HerreraB, JacobP III: Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese–Americans. J. Natl Cancer Inst.94 , 108–115 (2002).
  • Kandel DB , HuMC, SchaffranC, UdryJR, BenowitzNL: Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults.Am. J. Epidemiol.165 , 901–910 (2007).
  • Higashi E , FukamiT, ItohM et al.: Human CYP2A6 is induced by estrogen via estrogen receptor.Drug Metab. Dispos.35 , 1935–1941 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.